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Calpain inhibition mediates autophagy-dependent
protection against polyglutamine toxicity
FM Menzies1,10, M Garcia-Arencibia1,8,10, S Imarisio2,10, NC O’Sullivan2,9,10, T Ricketts1, BA Kent3,4, MV Rao5,6,7, W Lam2,
ZW Green-Thompson1, RA Nixon5,6,7, LM Saksida3,4, TJ Bussey3,4, CJ O’Kane*,2 and DC Rubinsztein*,1
Over recent years, accumulated evidence suggests that autophagy induction is protective in animal models of a number of
neurodegenerative diseases. Intense research in the field has elucidated different pathways through which autophagy can be
upregulated and it is important to establish how modulation of these pathways impacts upon disease progression in vivo and
therefore which, if any, may have further therapeutic relevance. In addition, it is important to understand how alterations in these
target pathways may affect normal physiology when constitutively modulated over a long time period, as would be required for
treatment of neurodegenerative diseases. Here we evaluate the potential protective effect of downregulation of calpains. We
demonstrate, in Drosophila, that calpain knockdown protects against the aggregation and toxicity of proteins, like mutant
huntingtin, in an autophagy-dependent fashion. Furthermore, we demonstrate that, overexpression of the calpain inhibitor,
calpastatin, increases autophagosome levels and is protective in a mouse model of Huntington’s disease, improving motor signs
and delaying the onset of tremors. Importantly, long-term inhibition of calpains did not result in any overt deleterious phenotypes
in mice. Thus, calpain inhibition, or activation of autophagy pathways downstream of calpains, may be suitable therapeutic targets
for diseases like Huntington’s disease.
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Huntington’s disease (HD) is a currently incurable, autosomal
dominant neurodegenerative disease resulting from the
expansion of the trinucleotide (CAG) repeat region of the
huntingtin (HTT) IT15 gene, encoding huntingtin protein (Htt).
In mutant Htt, the polyglutamine tract encoded by this region
contains over 35 glutamines and the length of the tract
correlates inversely with the age of disease onset, with longer
tracts resulting in earlier onset (reviewed in Imarisio et al.1).
HD is one of the 10 trinucleotide repeat disorders resulting
from expansions of polyglutamine tracts in different proteins.
These expansions cause disease by conferring toxic gain-of-
function properties onto the mutant proteins. Hence, one
strategy that has been considered for HD and related diseases
is to find ways of decreasing the levels of the mutant protein,
for instance by harnessing the cell’s capacity to degrade
such aggregate-prone proteins via (macro)autophagy.2–5
Autophagy involves the engulfment of cytoplasmic contents
by double-membraned autophagosomes, which then traffic to
lysosomes where their contents are degraded. Mutant
huntingtin, some other polyglutamine expanded proteins like
mutant ataxin 3, and proteins like tau (which mediates toxicity
in Alzheimer’s disease and related dementias) are autophagy
substrates and their clearance can be enhanced inDrosophila
and mouse models by autophagy upregulation, which also
reduces their toxicity.2–4,6
Calpains are a family of calcium-activated cysteine
proteases (reviewed in Ono and Sorimachi7) that inhibit
autophagy. Strategies that reduce calpain activity in cell
culture increase autophagy and decrease levels of
autophagy substrates, like mutant Htt. These effects are
likely to be mediated by Gsα, a heterotrimeric G-protein
subunit which is activated by calpain cleavage. Similar to
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calpain inhibition, siRNA knockdown of Gsα, or chemical
inhibition by NF449, induces autophagy and decreases
the number of aggregates resulting from the overexpression
of exon-1 Htt with an expanded polyglutamine repeat
region (HttQ74) in cell culture models.8 In addition to this
mechanism of autophagy upregulation by calpains, the core
autophagy protein ATG5 has also been demonstrated to be
cleaved and inactivated by calpains,9,10 suggesting that
calpains may act on a number of substrates to negatively
regulate autophagy.
In mammals, the two most abundantly expressed calpains
are μ-calpain and m-calpain, which differ in their affinity for
calcium and therefore the calcium concentration required for
their activation. Aswell as being regulated by calcium, they are
also controlled by an endogenous inhibitor, calpastatin
(CAST). Drosophila have four forms of calpain:11 CalpA and
CalpB are the conventional calpains formed by a recent
duplication in the Drosophila insect lineage, CalpC is also an
evolutionarily recent, but not highly conserved duplication
(data not shown) and is thought to be catalytically inactive,11
and CalpD (SOL) is a member of the unconventional family of
calpains. Drosophila does not appear to have any obvious
orthologs of CAST.
A role for calpains in HD has been investigated previously.
Following observations that shorter Htt fragments are more
toxic than full-length Htt,12 it was demonstrated that Htt can
be cleaved by both caspases13 and calpains14 to generate
these toxic, short fragments. Blocking Htt cleavage by
calpains by mutating their calpain cleavage sites decreases
Htt aggregation and toxicity.15 In addition, calpain activation
has been shown to be increased in HD patients compared with
controls.14
In this study, we have investigated a role for calpain activity
as a modulator of autophagy in both Drosophila and mouse
models of HD. To avoid confounding effects from alterations
in cleavage of Htt by calpain, we have used models
expressing short fragments of Htt, which do not contain
calpain cleavage sites and correspond to the shortest
fragments of huntingtin seen in patients.16 We demonstrate
that knockdown of CalpA in Drosophila is sufficient to both
reduce the number of Htt aggregates and the toxicity
associated with the expression of the mutant protein.
Importantly, we show that these effects are autophagy-
dependent. Furthermore, we show that overexpression of
CAST in mice results in enhanced autophagy and improves
locomotor function and delays tremor onset in a mouse
model of HD, as well as decreasing the number of Htt
aggregates seen in the brain. We extended the analysis of
CAST overexpressing mice to investigate the possible
adverse effects from long-term calpain inhibition or autop-
hagy upregulation but did not observe any obvious deleter-
ious effects.
Results
Calpain knockdown is protective in Drosophila expres-
sing mutant huntingtin and protection requires func-
tional autophagy. We have previously demonstrated that
siRNA knockdown of calpain in mammalian cell culture
results in an upregulation of autophagy and a decrease in
mutant Htt aggregation and toxicity.8 In order to extend this
finding in vivo, we investigated the effect of CalpA RNAi
knockdown in Drosophila expressing green fluorescent
protein (GFP)-tagged huntingtin exon-1 with an expanded
polyglutamine repeat (Httex1-Q46-eGFP)17 in the eye using
GMR-GAL4. Aged GMR-GAL4 Httex1-Q46-eGFP flies form
GFP-fluorescent huntingtin aggregates that can be easily
counted. After confirming that CalpA mRNA levels were
decreased by CalpA RNAi expression (CalpAKK101294 from
the Vienna Drosophila Resource Center, expressed in eyes
using GMR-GAL4) in heads of flies expressing Httex1-Q46-
GFP (Figure 1a), we observed that decreased CalpA levels
resulted in a clear reduction in the number of Httex1-Q46-
GFP aggregates in the eye, relative to the control flies
(Figure 1b). This reduction in aggregates is likely to reflect a
decrease in the soluble and oligomeric forms of mutant
huntingtin as well as the large aggregates, as these forms
have all been demonstrated to be altered by autophagy
induction.6 To confirm the phenotypes observed using the
CalpAKK101294 RNAi line, we used two insertions of a second
UAS RNAi construct (CalpACG7563R1 and CalpACG18152R2),
from the Japanese National Institute of Genetics (NIG-Fly
Stock Center), which had no sequence overlap with
CalpAKK101294. Both these lines were effective in decreasing
CalpAmRNA levels (Figure 1c), and expression in eyes using
GMR-GAL4 resulted in a decreased number of Httex1-Q46-
GFP aggregates (Figure 1d), similar to CalpAKK101294. To test
the contribution of autophagy to this decrease in aggregate
number, we assessed the effects of calpain knockdown in
flies with a loss-of-function allele for the key autophagy gene
Atg8a.18 In Atg8a mutant flies, reduction of CalpA levels was
unable to reduce Htt aggregate number (Figure 1e).
Figure 1 Calpain knockdown reduces Htt aggregation and protects against toxicity in Drosophila. (a) CalpA mRNA levels are decreased in heads of Httex1-Q46-eGFP flies
expressingCalpAKK101294 UAS-RNA (CalpAKK), compared with control. Rp49 was used as an internal mRNA control. Genotypes: w; GMR-GAL4/+; UAS-Httex1-Q46-eGFP/+ for
control (w1118) and w; GMR-GAL4/CalpAKK101294; UAS-Httex1-Q46-eGFP/+. (b) Downregulation of CalpA in the eye reduces the number of aggregates in male and female
Httex1-Q46-eGFP flies. (c) CalpA mRNA levels in adult flies are decreased using CalpACG7563R1 or CalpACG18152R2 UAS-RNAi lines expressed using da-GAL4, compared with
control. Rp49 was used as an internal mRNA control. Genotypes: UAS-dicer2; da-GAL4/+ for control and UAS-dicer2; CalpA CG7563R1; da-GAL4/+ or UAS-dicer2; da-GAL4/
CalpA CG18152R2 (d) Downregulation of CalpA in the eye using UAS-Dicer2 and NIG UAS-RNAi lines reduces the number of aggregates in female and male Httex1-Q46-eGFP
flies. Genotypes: UAS-dicer2; GMR-GAL4/+; UAS-Httex1-Q46-eGFP/+ for control and UAS-dicer2; GMR-GAL4/CalpACG7563R1; UAS-Httex1-Q46-eGFP/+ or UAS-Dicer2;
GMR-GAL4/+; UAS-Httex1-Q46-eGFP/CalpACG18152R2. (e) Loss of Atg8a abolishes the rescue of aggregate formation by downregulation of CalpA in Httex1-Q46-eGFP flies.
Genotypes: Atg8aKG07569/Y; GMR-GAL4/+; UAS-Httex1-Q46-eGFP/+ for control and Atg8aKG07569/Y; GMR-GAL4/ CalpAKK101294; UAS-Httex1-Q46-eGFP/+. (f) CalpA
knockdown increases the number of rhabdomeres per ommatidium in flies constitutively expressing mutant huntingtin in the eye (GMR-Q120). Genotypes: w; elav-GAL4/+;
GMR-Q120/+ for control and w; elav-GAL4/CalpAKK101294; GMR-Q120/+. (g) The protective effect on toxicity is lost in male flies lacking Atg8a. Genotypes: Atg8aKG07659/Y; elav-
GAL4/+; GMR-Q120/+ for control and Atg8aKG07659/Y; elav-GAL4/CalpAKK101294; GMR-Q120/+ All graphs show mean±S.E.M. Comparisons with controls were performed
using Student’s t-tests: NS, not significant; *Po0.05; **Po0.01; ***Po0.001
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To establish whether this reduction in aggregate number
correlated with an increase in cell survival, we used
the pseudopupil technique.19 Neurodegeneration in the
Drosophila eye can be observed as a decrease in the number
of visible rhabdomeres within each of the ommatidium that
make up the compound eye. Flies expressing the first exon of
huntington with an expanded polyglutamine repeat region of
120 in the eye (GMR-Q120) show a progressive decrease
in the number of visible rhabdomeres per ommatidium,20
a phenotype that was partially rescued upon CalpA
downregulation (Figure 1f). As was seen for the effect
on aggregation, this decreased toxicity was not observed
in GMR-Q120 flies in a mutant Atg8a background
(Figure 1g). In fact, decreasing CalpA in these autophagy-
defective flies increased the toxicity of mutant Htt, further
demonstrating a role for autophagy in the protective effect of
calpain inhibition.
CalpA downregulation is also protective in Drosophila
expressing other proteins associated with neurodegen-
eration. To test these effects in a related model with a
different readout, we expressed an epitope-tagged naked
stretch of 48 polyglutamines (Q48) in the fly eye using the
GMR-GAL4 driver.21 Expression of this protein causes
severe eye degeneration with loss of pigmentation in the
eye and formation of black necrotic-like spots (Figure 2a).
Downregulation of CalpA in Q48 flies led to a significant
reduction in the number of flies with black necrotic-like spots
in the eye, in both males and females (Figure 2b), demon-
strating a protective effect of reduction of CalpA levels against
neurodegeneration resulting from expression of pure poly-
glutamine proteins.
The protective effect of CalpA downregulation has also
been previously shown in flies overexpressing tau,22 which
aggregates intracellularly in Alzheimer’s disease and is
mutated in forms of frontotemporal dementia. However, this
study argued that the protection was via interference of tau
proteolysis by calpains, and the mutant alleles used do not
disrupt the calpain coding regions (www.flybase.org) and only
reduced calpain activity by 5–10%. We were able to confirm
that calpain knockdown using the CalpAKK101294 line
(Figure 2c) protected against tau toxicity, as measured by
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Figure 2 Downregulation of CalpA ameliorates Q48 and tauWT eye phenotypes. (a) Expression of a stretch of 48 glutamines in the eye (Q48) causes severe loss of
pigmentation and presence of blacknecrotic-like spots (labelled with a white arrow) compared with WT flies. Genotypes: w; GMR-GAL4/+ for control (w1118) flies and w; GMR-
GAL4/+; UAS-Q48.myc.flag/+ for Q48. (b) Downregulation of CalpA using CalpAKK101294 reduces the number of black necrotic-like spots of Q48 flies. Fisher’s exact test was
applied for statistical comparisons between the control and test genotypes. BS= black necrotic-like spots; no BS= absence of black necrotic-like spots. (c) CalpAmRNA levels
are decreased in the eye of flies expressing both tauWT and CalpAKK101294 compared with controls expressing tauWT alone. Rp49 was used as an internal mRNA control.
Genotypes: w; GMR-GAL4/+; UAS-tauWT/+ and w; GMR-GAL4/ CalpAKK101294; UAS-tauWT/+. (d) Downregulation of CalpA using CalpAKK101294 increases the eye area of flies
expressing tauWT. Genotypes: Atg8aKG07659/Y; GMR-GAL4/+; UAS-tauWT/+ for control and Atg8aKG07659/Y; GMR-GAL4/CalpAKK101294; UAS-tauWT/+. (e) Loss of Atg8a
abolishes the protective effect of CalpA downregulation on tauWT. All graphs show mean± S.E.M.; comparisons with controls were performed using paired Student’s t-tests. NS,
not significant; *Po0.05; **Po0.01
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the eye area of flies expressing wild-type (WT) tau23
(Figure 2d). As we observed for the polyglutamine proteins,
protection due to decreased CalpA levels required functional
autophagy as the protective effect was lost in flies on an Atg8a
loss-of-function background (Figure 2e). Decreasing CalpA
levels is therefore protective against diverse proteins asso-
ciated with neurodegenerative disorders and requires func-
tional autophagy.
CAST overexpression increases autophagy and reduces
Htt levels in a mouse model of HD. To test these
phenomena in a mammalian system, we used mice over-
expressing CAST, which inhibits calpain activity.24 CAST
expression was driven by a thymocyte differentiation antigen
1.1 (Thy1.1)-expression cassette and was therefore limited
to the brain. Western blotting in brain tissue isolated
from transgenic mice overexpressing CAST demonstrated
increased levels of LC3-II, a modified form of LC3
known to associate with autophagosomes and the only
known marker for autophagosome number (Figure 3a).
This increase in LC3-II is therefore compatible with an
increase in autophagy in CAST overexpressing mice.
Although an increase in LC3-II might, in principle, arise
from enhanced autophagosome formation or impaired
autophagosome degradation, the latter is unlikely in view
of our previous data in cells showing that CAST increased
autophagosome formation8 and the dependence of Droso-
phila calpain knockdown phenotypes on functional Atg8a,
described above. The HD model mice (N171-82Q) over-
express an exon-1 fragment of the huntingtin protein with an
expanded polyglutamine region of 82Q. They have a
progressive neurodegenerative disease and show signs of
motor impairment on rotarod and grip-strength tests, as
well as increased tremors and intracellular huntingin
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Figure 3 Calpastatin overexpression enhances autophagy in mice and reduces Htt levels. (a) LC3-II levels in brain lysates from mice overexpressing calpastatin (CAST, white
bar) and littermate controls (WT, black bar) were assessed by western blotting, blots were also probed for actin as a loading control. Graph shows densitometric analysis of LC3-II-
levels relative to actin. Control condition is set to 100%. (**Po0.005, t-test). (b) CAST overexpression in double-transgenic calpastin, N171-82Q mice (CAST HD) relative to
single-transgenic N171-82Q mice (HD). (c) LC3-II levels in brain lysates from mice overexpressing calpastatin (CAST HD, white bar n= 9) on an N171-82Q background
(HD, black bar n= 8). Graph shows densitometric analysis of LC3-II-levels relative to actin. (d) Levels of p62 in brain lysates from HDmice (HD, black bar n= 8) and HD mice also
overexpressing (CAST HD, white bar n= 9). Graph shows densitometric analysis of p62 levels relative to actin (*Po0.05, t-test). (e) Soluble huntingtin (Htt) levels in the
cytoplasmic fraction of brain lysates from HDmice overexpressing CAST in comparison to control, HD mice. Graph shows densitometric analysis of Htt levels relative to actin (HD
n= 8, CAST HD n= 9) (*Po 0.05, t-test). (f) The number of huntingtin-positive aggregates in the motor cortex of N171-82Q mice was reduced by the overexpression of CAST.
Examples of aggregates are highlighted by arrows. Scale bar represents 50 μM and is valid for both images. Mean number of aggregates per field was quantified in three mice per
group and the quantification is shown in the graph (***Po0.001, t-test). All graphs represent mean and error bars represent S.E.M.
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aggregates. In these mice, the transgene is driven by the
mouse prion protein promoter resulting in expression
predominantly in the brain (as with the CAST overexpres-
sing mice), unlike the R6/2 mice where the transgene is
expressed widely in the peripheral tissues such as
muscle.25
To investigate whether calpain inhibition confers protection
against neurodegeneration, we expressed CAST in N171-
82Q mice (Figure 3b). Mice expressing the expanded
polyglutamine transgene (HD) were compared with the
littermates expressing both mutant huntingtin and CAST
(CAST HD). Western blot analysis of the brains of HD mice
demonstrated that overexpression of CAST resulted in an
increase in LC3-II levels (Figure 3c); however, this increase
was relatively small and did not reach statistical significance.
This may be due to the presence of mutant Htt interfering with
the upregulation of autophagy by CAST, but may also be due
to lack of sensitivity of the LC3-II western blot autophagy assay
in mouse brain, especially as this assay in vivo only allows one
a snapshot of the autophagosome load without any direct
inference of flux, as one cannot easily block flux in vivo with
lysosomal inhibitors. However, an increase in functional
autophagy in these CAST HD mice was consistent with the
observed decrease in the autophagy adaptor protein p62,
which is also degraded by autophagy (Figure 3d). We have
previously demonstrated that mutant Htt is also degraded by
autophagy,2 and in agreement with an upregulation of
autophagy in these mice, we saw a decrease in the levels of
SDS-soluble mutant Htt in the cytoplasmic fractions of brain
lysates fromCAST transgenic mice (Figure 3e).We also saw a
dramatic decrease in the number of Htt-positive aggregates in
the motor cortex of HD mice when they also expressed CAST
(Figure 3f).
CAST overexpression is protective in a mouse model of
HD. In addition to the cellular effects of CASToverexpression
in HD mice, we sought to investigate if disease progression
was also altered in these animals. Behavioral tests were
carried out on both HD and CAST HD mice beginning at
10 weeks of age, around the time that the first signs of
disease manifest, and then repeated every fortnight. Motor
coordination was assessed using rotarod performance.
Throughout the trial period CAST-overexpressing mice
displayed a greater ability in the rotarod test than the
single-transgenic HD littermates (Figure 4a and
Supplementary Figure 1a). As another measure of locomotor
activity, the open field test was used. CAST HD mice were
seen to have increased locomotor activity at all stages tested
relative to HD mice (Figure 4b and Supplementary Figure 1b).
A reliable phenotype seen in the N171-82Q mice is the onset
of tremors from an early age. Overexpression of CAST
delayed the age of onset of tremors in the HD mice
(Figure 4c). CAST overexpression did not influence the
weight of the HDmice (Figure 4d and Supplementary Figure 1c).
Grip strength is also decreased in HD mice relative to control
mice (Supplementary Figures 1d and e), and there was some
protection by overexpression of CAST at later stages of
disease (Figures 4e and f). HD mice have a decreased
lifespan. According to our Project Licence, animals were
killed when they showed medium severity symptoms,
identified by signs such a weight loss of 20%, continuous
tremor, hunching or subdued behavior when provoked.
Although this compromises accurate lifespan assessments,
CAST HD mice had median survival of 141 days compared
with 128 days in single-transgenic HD mice (Figure 4g;
P= 0.08).
Long-term overexpression of CAST in the brain is not
obviously deleterious. The data described above suggest
that decreased calpain activity can protect against neurode-
generation by enhancing the clearance of mutant huntingtin
via autophagy. The ultimate aim of work such as this study is
to identify potential therapeutic targets of relevance for HD.
Such treatments, once developed, would have to be tolerated
long-term by patients without any deleterious effects. We
therefore sought to establish whether long-term inhibition of
calpain activity in the brain and therefore long-term upregula-
tion of autophagy resulted in any neurological consequences
in mice. SHIRPA (SmithKline Beecham, Harwell, Imperial
College, Royal London Hospital, phenotype assessment)26
was used as a primary screen to assess 1.5-year-old CAST
mice for behavioral alterations compared with the non-
transgenic littermate controls. SHIRPA is a phenotype screen
that can identify broad neurological or muscular dysfunction.
The test includes assessment of body position, limb tone,
spontaneous activity, coordination and tail elevation as part of
30 semiquantitatively measured endophenotypes. This com-
prehensive assessment of phenotypes can reflect potential
deficits in a variety of functions ranging from autonomic to
neuropsychiatric and moto-sensory capabilities. A total of 22
non-transgenic mice were assessed (11 female and 11 male)
and 19 CAST mice (11 female, 8 male), and no abnormal
signs were observed in CAST mice (Supplementary Table 1).
In addition, no change was seen in the locomotor activity of
the mice as assessed by open field testing (Figure 5a), the
grip strength of CAST-overexpressing mice was not altered
relative to controls (Figures 5b and c) and there was no
change in weight (Figure 5d). In order to investigate the
cognitive ability of these mice, spontaneous novel object
recognition tests were employed. Mice presented with two
objects, one familiar and one novel, will spend longer
investigating the novel object. The ratio of time spent
investigating the novel and familiar object can be used as a
readout for the recognition of the object by the mouse and
therefore memory and cognitive ability. No difference was
observed between CAST and WT mice in this test at a 3 or
24 h delay (Figure 5e). There was also no difference in the
amount of exploration during the sample or choice phase of
the CAST and WT mice. One CAST mouse was removed
from the 24 h delay analysis because of low (o2 s)
exploration during the ‘Sample’ phase.
Gross brain morphology, assessed by hematoxylin and
eosin staining and microscopy revealed no major alterations
(an example is shown in Figure 5f). Finally, survival of the
CAST mice was assessed relative to control mice. These
transgenic mice are on a C57BL/6 background and as such
are prone to developing a skin condition, ulcerative
dermatitis.27 Although this is not life-threatening, any mice
developing this condition were culled to reduce discomfort and
excluded from the survival study. No change in frequency was
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Figure 4 CASToverexpression improves motor performance and the severity of tremors in a transgenic mouse model of HD. (a) Calpastatin overexpression (CAST HD,
grey line) improves best rotarod performance over a trial of three tests compared with control N171-82Q mice (HD, black line). Overall effect obtained from all age points,
**Po0.005 (two-way ANOVA). (b) CASToverexpression in N171-82Q mice (CAST HD, grey line) improves locomotor activity measured by open field test in comparison to
control group (HD, black line). Overall effect from all the age points was **Po0.01 (two-way ANOVA). (c) The number of mice with tremors was significantly improved by
CASToverexpression (CAST HD, white bars) in N171-82Q mice at 12 weeks (*P= 0.0112), 14 weeks (*P= 0.0286) and 16 weeks of age (*P= 0.0369) in comparison to the
control group (HD, black bars) (Mann–Whitney U-test). (d) Body weight is not changed in 171-82Q transgenic mice when they also overexpress CAST. (e) Forelimb grip
strength in N171-82Q mice (black line) compared with mice also overexpressing CAST (grey line). Overall effect from all age the points, (*P= 0.0397) (two-way ANOVA)
(f) Grip strength of all limbs in N171-82Q mice (black line) compared with mice also overexpressing CAST (grey line) (P= NS, two-way ANOVA). (g) The median survival age
of CAST-overexpressing mice (CAST HD) is compared with the control group (HD) (128 days versus 141 days, P= 0.08, Mantel–Cox test, 1 tailed). All graphs represent
mean and error bars represent S.E.M.
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observed in the frequency of the dermatitis in CAST,
compared with the littermate control mice. CAST overexpres-
sion did not significantly change the lifespan of the mice
(median survival CAST 103 weeks n=46, WT 108 weeks
n= 49, not significant; no difference was seen in survival when
comparing males and females separately, data not shown).
Although our data suggest that CASToverexpression/calpain
inhibition in the brain is well tolerated, further models with
whole-body CASToverexpression will be required to test if this
is similarly well tolerated in all organs.
Discussion
In this study we demonstrate that reducing CalpA levels in
Drosophila results in protection against phenotypes resulting
from Htt overexpression in a manner dependent on functional
autophagy. This protective effect is also seen in mammalian
models of HD as overexpression of the endogenous calpain
inhibitor, CAST, has a beneficial effect in mice overexpressing
Httex-1 with an expanded polyglutamine repeat. As this short
Htt fragment does not contain any calpain-binding sites and is
the same in length as the short, toxic fragments that have been
Figure 5 Calpastatin overexpression does not cause an overt phenotype in aged mice. (a) In 1.5-year-old mice calpastatin overexpression (CAST) did not alter locomotor
activity, as measured by open field test, in comparison to control group (WT). (b) Forelimb grip strength in wild-type littermate controls (WT) compared with mice overexpressing
CAST. (c) Grip strength of all limbs in WT control mice (black bar) compared with mice overexpressing CAST. (d) Body weight is not changed in CAST- transgenic mice (CAST)
compared with the littermate controls (WT). Males were slightly heavier that females in both genotypes. (e) Mice did not show cognitive impairment based on spontaneous novel
object recognition testing. Discrimination ratio plotted on the graphs represents the preference showed by the mice for investigating the novel object during the ‘Choice’ phase,
calculated as (time spent exploring the novel object− time spent exploring the sample object)/(total time spent exploring). (f) Hemotoxylin and eosin staining of CAST transgenic
and control (WT) mice did not demonstrate any changes in morphology. Examples of staining in the cerebellum are shown at low magnification (top images, scale bar represents
200 μm) and higher magnification (lower images, scale bar represents 50 μm). (g) Survival was not altered in mice overexpressing CAST compared with the littermate controls
(WT) (median lifespan; CAST 103 weeks, n= 46, WT, 108 weeks, n= 49, P=NS, Mantel–Cox test). In all graphs, white bars represent CAST- transgenic mice and black bars
represent WT, littermate controls, error bars represent S.E.M.
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implicated in the toxicity of huntingtin,16 this protective effect
cannot be due to decreased calpain cleavage of mutant Htt.
We have observed that overexpression of CAST in mice
results in a large decrease in the number of aggregates
present in the brain and a more modest decrease in levels of
SDS-soluble Htt. However, the preferred substrates for
autophagic degradation are likely to be the SDS-soluble
oligomeric forms. The large aggregates seen by light micro-
scopy in HD are never membrane bound and are much larger
than the typical 1-micron diameter of an autophagosome.
Decreasing oligomer levels will impact on both the SDS-
soluble pool and the numbers of aggregates, as the oligomers
are the precursors of the aggregates. As the SDS-soluble pool
likely has a greater proportion of monomers than oligomers,
the change in this pool with autophagy induction would be
expected to be rather modest. Furthermore, the ratio of
aggregates to soluble protein is controlled by the aggregation
kinetics of the mutant protein. Aggregate formation correlates
with the total concentration of the mutant protein.28 Therefore
as the total protein concentration (soluble and aggregated)
decreases the number of aggregates will decrease until the
concentration is below the threshold required for protein
aggregation. This may be an additional factor that explains
why the aggregate number changes more dramatically than
the SDS-soluble mutant huntingtin.
Although the loss of autophagy in flies abrogates the
protective effect of decreased CalpA levels, it is still possible
that factors other than autophagy upregulation contribute to
the protective effect seen in mouse HD models, as alterations
in calpain activity have been associated with HD in a variety of
ways. Calpain activation has been demonstrated in the brains
of HD patients in both the putamen29 and caudate.14 This
activation is not seen either in age-matched controls or in the
regions of the brain that are less vulnerable in HD such as the
frontal cortex.29 It may be explained by an increase in neuronal
calcium levels caused by excitotoxicity, which has been
implicated in HD via a number of mechanisms.30
Calpain dysregulation and a protective effect of calpain
inhibition have also been suggested in a variety of other
neurodegenerative diseases. In Alzheimer’s disease calpains
have been shown to be aberrantly activated29 and have been
implicated in the processing of amyloid precursor protein31
and tau.32,33 Consistent with this, a decrease in CAST in
brains of Alzheimer’s disease patients has been reported24
and overexpression of CAST is protective in mice injected with
kainic acid, a model of excitotoxicity associated with Alzhei-
mer’s disease.24 Similarly, marked depletion of CAST has
been seen in mice expressing P301L-mutant tau and over-
expression of CAST prevents a diverse range of tauopathy-
associated phenotypes seen in these mice, including delaying
disease onset by 3 months.34 Overexpression of CAST is also
protective in mouse models of Parkinson’s disease. Calpains
have been suggested to cleave α-synuclein and enhance its
aggregation properties.35 Transgenic mice overexpressing
A30P mutant α-synuclein along with CAST showed a
decreased number of α-synuclein positive aggregates and
decreased neuropathology compared with mice overexpres-
sing A30P mutant α-synuclein alone.36 Although the mechan-
ism for the protective effect of CAST in these cases has been
suggested to be decrease the cleavage of the relevant protein,
these proteins have also been demonstrated to be substrates
for autophagic clearance.3,37 This hints that autophagy
upregulation could contribute to the protective mechanisms,
as we have seen in HD in this study. This has not yet been
formally tested, but could suggest a double-protective effect
for decreasing calpain activity in a range of neurodegenerative
diseases. It must also be considered that the protective effect
seen in the HDmouse model in this study is relatively mild, the
potential double-protective effect would not apply to this model
expressing only exon-1 Htt, and the speed of disease
progression in this model relative to the very slow onset in
humans may reduce the window of opportunity for reducing
protein levels and relieving disease signs. Investigating the
protective effect of calpain inhibition in other HD models (e.g.,
those expressing longer Htt variants) may therefore be of
value. Despite this, when considered with the observations in
this study that decreasing calpain activity over long periods of
time does not have obvious deleterious effects in mice, calpain
inhibition could be a promising therapeutic strategy to explore
in these diseases.
Materials and Methods
Fly stocks. For knockdown of CalpA the UAS-RNAi line KK101294
(CalpAKK101294), the w1118 control stock (60100) from Vienna Drosophila Resource
Center (VDRC, http://stockcenter.vdrc.at/control/main),38 the UAS-RNAi lines
CG7563R1 or CG18152R2 (CalpACG7563R1 or CalpACG18152R2), or the w1118
control from the Japanese National Institute of Genetics (NIG-Fly, http://www.shigen.
nig.ac.jp/fly/nigfly/) were used. The KK construct targets CalpA exons between
genomic coordinates 15314791 and 15315502 (release 5.57), and both NIG-Fly
lines target CalpA exons between genomic coordinates 15313689 and 15314791;
note that CG7563 and CG18152 are both synonyms for CalpA (www.flybase.org).
GAL4 drivers used were P{GAL4-ninaE.GMR}12 (GMR-GAL4),39 P{GAL4-da.G32}
(da-GAL4),40 P{GAL4-elav.L}2 (elav-GAL4)41 and P{GawB}elavC155 (elav-
GAL4c155).42 Other fly stocks used were UAS-tauWT (tauWT, gift of Mel Feany),23
UAS-Httex1Q46-GFP (Httex1-Q46-eGFP, gift of Sheng Zhang),17 P{GMR-HTT.
Q120}4.62 (GMR-Q120, gift of G Jackson),20 P{UAS-Q48.myc.flag}31 (Q48, gift of
Lawrence Marsh),21 P{SuPor-P }Atg8aKG07569 (Atg8aKG07569, Bloomington Stock
Center),43 P{UAS-Dicer2, w[+]} (UAS-Dicer2, VDRC).
Aggregate counting in Huntingtin-mutant flies. Flies expressing
GFP-tagged expanded huntingtin exon 1 in the eye (Httex1-Q46-eGFP17) were
crossed to UAS-RNAi line CalpAKK101294 or to w1118 control flies (in the presence or
absence of the loss-of-function allele Atg8aKG07569). For the UAS-RNAi lines from
the NIG-Fly stock, virgins UAS-dicer2; CalpACG7563R1 or UAS-dicer2; +;
CalpACG18152R2 were crossed to w; GMR-GAL4; UAS-Httex1-Q46-eGFP males.
The progeny were collected and analyzed 15 days post eclosion or 35 days post
eclosion in the case of NIG-Fly UAS-RNAi lines, with age-matched controls imaged
concurrently. The crosses were performed at least four times with at least four flies
analyzed per cross. All crosses were performed and maintained at 25 °C. Images
were acquired using a fluorescence stereomicroscope (Leica MZ16 F, Milton
Keynes, UK). GFP intensity or the number of aggregates per eye were measured
using ImageJ (U.S. National Institutes of Health, Bethesda, MD, USA; http://ImageJ.
nih.gov), data were exported to GraphPad Prism 5 (GraphPad Software, San Diego,
CA, USA) and statistical significance was determined using two-tailed unpaired
Student’s t-tests for the experiment with CalpAKK101294 or one-tailed unpaired
Student’s t-tests for CalpACG7563R1 and CalpACG18152R2.
Pseudopupil analysis on mutant huntingtin flies. Analysis was
performed as previously described.19 In brief, a stock line constitutively expressing
in the eye mutant huntingtin exon 1 (GMR-Q120)20 with either CalpAKK101294 or its
background control was crossed to the neuronal driver elav-GAL4C15542 at 25° C.
For analysis using the Atg8aKG07659 loss-of-function line, Atg8aKG07659 virgins
carrying either CalpAKK101294 or its background control were crossed to w; elav-
GAL4; GMR-Q120 males. The number of rhabdomeres per ommatidium was
scored in progeny of the above crosses at 3 days post eclosion. Statistical analysis
Calpain inhibition mediates autophagy-dependent protection
FM Menzies et al
9
Cell Death and Differentiation
was performed using Student’s t-tests on data from at least five independent
experiments, each based on ~ 10 individuals for each genotype, scoring 15
ommatidia per eye.
TauWT eye area analysis. Virgins of w; GMR-GAL4;UAS-tauWT were crossed
either with CalpAKK101294 or with w1118 control males. For analysis using the
Atg8aKG07659 loss-of-function line, Atg8aKG07659 virgins carrying either Cal-
pAKK101294 or its background control were crossed with w; GMR-GAL4;UAS-tauWT
males. The progeny were collected and analyzed 3 days post eclosion, with age-
matched controls imaged concurrently. All the crosses were performed five times at
25 °C with at least six male flies analyzed per cross. Images were acquired using a
× 7.5 light microscope (SMZ-100, Nikon, Kingston upon Thames, UK). Eye area was
measured using ImageJ blind to genotype. Data were exported to GraphPad Prism
5 (GraphPad Software Inc.) for statistical analysis. Statistical significance was
determined using Student’s t- tests with five independent experiments.
Semiquantitative PCR. Total RNA was purified from 440 fly heads (GMR-
GAL4 crosses) or from 3 flies (da-GAL4 crosses) collected in TRIzol reagent
(Invitrogen, Paisley, UK). cDNA was produced using SuperScript III First Strand kit
(Invitrogen), 50 μM oligo-dT primer and 2 μg DNase-treated RNA. Amplification of
Rp49 mRNA was used to control for cDNA concentration in the polymerase
chain reaction (PCR). Primers used were: Rp49-F: 5′-CCGACCACGTTACAAGAAC
TCTC-3′, Rp49-R: 5′-CGCTTCAAGGGACAGTATCTGA-3′, CalpA-F: 5′-TCC
GAGGTGCAGGACTATGA-3′ and CalpA-R: 5′-GTTCTTCTCCGTGGAGTGCA-3′.
PCR conditions were 95 °C for 30 s; 60 °C 30 s; and 72 °C for 1 min repeated for
20 cycles for Rp49 and 30 cycles for CalpA. Samples from at least three
independent crosses for each genotype were analyzed. PCR products were
visualized with ethidium bromide on a gel, and band intensities quantified using
ImageJ.
Characterisation of CalpA KK-RNAi line CalpAKK101294. We verified
that the CalpAKK101294UAS-RNAi line was not inserted at the landing site that
affected the tio gene44 by crossing virgins of elav-GAL4C15542 with either
CalpAKK101294 or w1118 (60100 stock, VDRC Stock Center, http://stockcenter.vdrc.at/
control/main) males. The progeny of both crosses had normally inflated wings (data
not shown), suggesting that they harbour the targeted insertion at the anticipated
genomic site.44
Mouse models. We used HD-N171-82Q mice backcrossed on a C57BL/6J
background for more than ten generations. These mice carry an N-terminal
fragment expressing the first 171 amino acids of human huntingtin with 82
glutamine repeats under the mouse prion promoter.45 CAST- transgenic mice
express CAST throughout the cortex and hippocampus under the control of the Thy
1.1 promoter.24 Mice were genotyped by PCR with DNA extracted from ear-clips at
3 weeks of age (primer sequences available on request). To generate the double-
transgenic mice, we crossed N171-82Q heterozygous males with Thy-Cast
heterozygous females. All studies and procedures were performed under the
jurisdiction of appropriate Home Office Project and Personal animal licenses and
with local Ethics Committee approval.
The following signs were used as humane end points for the mice, which resulted
in euthanasia: marked loss of appetite and fluid intake, staring coat, hunched posture
and subdued behavior, or 20% weight loss over a period ofo3 days.
Behavioral analysis. Animals were housed together in groups of mixed
genotypes, and experienced observers were blind to the genetic status during
testing. Mice were carefully monitored daily, and weighed every week. A minimum of
eight males per genotype and line were analyzed for specific tests. They were
housed under conventional conditions in individually ventilated cages with food and
water ad libitum.
We assessed the motor performance at 10, 12, and 14 weeks of age with a
rotarod apparatus (Accelerating Model, Ugo Basile, Biological Research
Apparatus, Varese, Italy). The mice were given training sessions for two
consecutive days to acclimatize them to the apparatus and on the third day, the
definitive testing took place. On the first training day, the mice had three trials at a
constant speed of 4 r.p.m. In each trial, the animals were put on the rotarod for a
maximum of 300 s. On the second day, the training took place at a constant speed
of 10 r.p.m. (three trials). Day 3 was the testing day, where the speed was
accelerated from 3 to 30 r.p.m. in 300 s. A minimum of 10 min break was given
between each trial. The latency to fall was taken as the maximum value reached
over the three trials.
Grip strength and tremor monitoring was also performed at 10, 12 and 14 weeks
of age. Grip strength was monitored quantitatively by using a grip strength meter
(Bioseb, Vitrolles, France). The mice were held above the apparatus grid with their
front paws (forelimb grip) or all four paws (all limb grip) grasping the grid, then
pulled back by the tail following the axle of the sensor, horizontally and steadily,
until they released the grid. The apparatus was used in the peak mode, the
recorded value corresponding to the maximum force produced by the animal.
Forelimb grip strength as well as all limb grip strength was measured three times
and the average value was taken. For tremors, the mice were placed on a grid in a
clear perspex cylinder. We recorded tremor for 2 min and scored the mice as
follows: 0, none; 1, tremor.
Aged-CAST mice were also tested for rotarod and grip strength performance.
SHIRPA assessment was completed as previously described.26
Spontaneous novel object recognition. Recognition memory was
assessed at 19 months of age, using a spontaneous novel object recognition
(SOR) paradigm. A total of 18 CAST mice and 8 non-transgenic littermate controls,
were housed in groups of 2–3 on a 12-h light cycle (lights on 19:00–07:00) and
testing was performed during the dark phase of the cycle. Mice were provided with
ad libitum access to water, but food was restricted beginning 5 days before the start
of testing to maintain body weight to 85–90% their free-feeding weight. Mice were
handled for 2 days before testing.
SOR testing took place in a Y-shaped apparatus (previously described in46), made
of homogenous opaque white perspex. Walls were 30 cm high, and each arm was
16 cm in length and 8 cm wide. A digital video camera was mounted above the
Y-maze to record the trials. One arm was used as the start arm, and the other two
arms were used to present the testing stimuli (randomly shaped junk objects
~ 10 cm × 4 cm × 4 cm) secured to the floor of the maze with Blu-tack. All mice were
habituated to the apparatus for three consecutive daily sessions in which they were
placed in the empty apparatus for 5 min and allowed to freely explore.
Testing consisted of two phases. During the ‘Sample’ phase, a mouse was shown
two identical sample objects and allowed to explore for 5 min. The mouse was then
removed from the maze and placed back in its homecage. After a pre-determined
delay of 3 or 24 h, the mice were then placed back into the Y-maze for the ‘Choice’
phase and shown one copy of the sample object and one novel object. All mice were
tested with a 3 h delay and then 5 days later were tested with a 24 h delay. The maze
and objects were wiped with a 50% ethanol solution between trials and the side of the
maze in which the novel object was presented, was counterbalanced.
Exploration was defined as a mouse directing its nose to an object at a distance of
2 cm or less. Climbing on, sitting on or chewing the object was not included as
exploration. The experimenter scored exploration using a computer program
JWatcher_V1.0, written in Java (http://www.JWatcher.ucla.edu). The program had
two keys corresponding to the two objects. Exploration was recorded by pressing the
appropriate keys at the onset and offset of a bout of exploration.
For the ‘Choice’ phase, discrimination ratios (D2) were calculated as the time
spent exploring the novel object minus the time spent exploring the sample object
divided by the total exploration time. Because of rodents’ innate preference toward
novelty, a D240, which suggests a preference toward exploring the novel object, is
thought to reflect a memory for the sample object.
Protein extraction and western blot analysis. Brains were frozen
immediately after removal and stored at − 80 °C for all possible genotypes. They
were mechanically homogenized in lysis buffer containing 50 mm Tris, pH 7.4, 0.5%
Triton X-100 and protease inhibitor cocktail. The homogenate was centrifuged at
13 400 g at 4 °C, the supernatant was removed and used for western blot. Cell
pellets were lysed on ice in Laemmli buffer (6.5 mM Tris-HCl, pH 6.8, 2% sodium
dodecyl sulphate (SDS), 5% β-mercaptoethanol, 10% glycerol, 0.01% Bromophenol
blue and protease inhibitors) for 30 min. Proteins were separated on 12% SDS-
polyacrylamide gels and transferred onto PVDF membranes (Hybond enhanced
chemiluminescence (ECL) membrane, GE Healthcare, Little Chalfont, UK).
Membranes were blocked by incubation in 5% dried milk in PBS and 0.1%
Tween-20, pH 7.6. The primary antibodies used were anti-LC3 (1 : 10 000; Novus
Biologicals, Cambridge, UK), anti-p62 (1 : 1000; BD, Oxford, UK) anti-actin (1 : 1000;
Sigma, Dorset, UK). Horseradish peroxidase-conjugated antibodies (GE Healthcare;
1 : 2000) were then added and immunoreactive bands were detected with ECL
reagent (GE Healthcare). Quantification of western blots was carried out using
ImageJ software and band intensities were normalized to actin levels.
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Immunohistochemistry. Sections (30 μm) of mice brains were analyzed for
neuronal inclusions according to the protocol of Davies et al.47 The sections
were labelled with anti-huntingtin antibody by free-floating immunohistochemistry
(EM48, Chemicon, Millipore, Watford, UK). Staining was performed by
peroxidase labelling using Vectastain avidin:biotinylated enzyme complex (ABC)
kit and visualized with DAB reagent (Vector Laboratories, Peterborough, UK).
Inclusions were counted in the piriform cortex and motor cortex in three fields on at
least three sections per animal at a magnification of × 100 (Zeiss Axioskop2, field
diameter 0.2 mm). Aggregates were photographed and the diameter was measured
using Zeiss axiovision software (Zeiss, Cambridge, UK).
Sections (10 μm) of brain were analyzed by hematoxylin (Vector laboratories) and
eosin (Sigma) staining. Sections were hydrated, immersed in hematoxylin (45 s),
rinsed and placed in 95% ethanol (30 s). Sections were then stained with eosin Y
(3 min) followed by graded ethanol submersion (70–100%), before xylene (5 min) and
mounting in Depex followed by light microscopy assessment (Zeiss Axioscop 2,
MRC5 camera).
Statistics. Significance levels for comparisons between the groups were
determined with t-tests, repeated measure, factorial ANOVA, two-way ANOVA or
Fisher’s exact test, where appropriate, for parametric data and with Mann–Whitney
U-tests for non-parametric data, for survival curves Log-rank (Mantel–Cox) test was
employed. All analyses were carried out using the GraphPad Prism, version 5
(GraphPad Software, La Jolla, CA, USA).
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